AGMB Company Profile and Key Details

AgomAb Therapeutics N.V. American Depositary Shares has 49.22 million shares outstanding. The public float is 13.30 thousand shares, elevated short interest at 0.34% of float. This equals 166.64 thousand shares. The short ratio is 1.44 days.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Short-term trend indicators are mixed aligned (SMA20 3.16%, SMA50 3.16%, SMA200 3.16%). The stock remains hovering near 52-week lows, trading -3.84% below its high and over 26.46% above its low. Average 10-day trading volume of 156.92 thousand shares is in line with the 3-month average of 158.40 thousand, indicating normal recent market interest.

AgomAb Therapeutics N.V. American Depositary Shares (NASDAQ:AGMB) closed at $11.32 USD, gaining $0.66 (6.19%) from the previous close of $10.66. The stock is currently mid-range between its 52-week high and low $9.00 and $17.45. With a market capitalization of about $556.64 million, AgomAb Therapeutics N.V. American Depositary Shares is classified as a small-cap and shows lower-than-market volatility (beta ~0.00). Key stats such as the average daily volume over the past year has been around 224.20 thousand shares, trading with heavier-than-usual volume. Headquartered in Antwerp, None, AgomAb Therapeutics N.V. American Depositary Shares operates in the Healthcare sector and the Biotechnology industry. Led by CEO Tim Knotnerus, the company employs approximately 57 people and listed since May 29, 2024. AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs.

Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 0 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $36.00 to $28.00. The high target offers 243.84% upside. The low target suggests 167.43% downside. The mean target is $32.00. This offers 205.64% upside.

Our AI price prediction model suggests that AgomAb Therapeutics N.V. American Depositary Shares stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -19.1%, with price expected at $8.47 by April 28, 2026, within a range of $7.66 to $9.26 3-Month Outlook: Projected fall of -80.04%, reaching $2.09 by July 13, 2026, with a range of $1.98 to $2.21. 1-Year Outlook: Projected loss of -99.9%, with price at $0.01 by April 14, 2027, within a range of $0.00 to $0.20.

currently trading near 52-week highs band. Valuation shows AgomAb Therapeutics N.V. American Depositary Shares trading at a premium to the broader market with a P/E of -6.93. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $32.00, suggesting 205.64% upside. Our AI forecast model points to short-term weakness (-19.1% over two weeks), a medium-term fall (-80.04% over three months), and a longer-term loss (-99.9% over one year), with expected trading ranges indicating moderate volatility.

AgomAb Therapeutics N.V. American Depositary Shares trades at a P/E ratio of -6.93, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 The P/FCF stands at 0.0, also above market averages.